Panel of bar charts showing the key secondary endpoints of mean percent change in BMI from baseline for pediatric patients with type 2 diabetes and mean change in weight from baseline for adult patients with T2D. SURPASS-PEDS studied Mounjaro as add-on to metformin and/or basal insulin vs placebo over 30 weeks in pediatric patients 10 years of age and older with T2D. The mean baseline BMI was 33.9 kg/m2, 37.7 kg/m2, 35.8 kg/m2, and 34.7 kg/m2 for Mounjaro 5 mg, Mounjaro 10 mg, pooled Mounjaro (5 mg and 10 mg), and placebo, respectively. Patients in the Mounjaro 5 mg group (n=32) had a -6.9% change from baseline. Patients in the Mounjaro 10 mg group (n=33) had a -10.8% change from baseline. Patients in the pooled Mounjaro group (n=65) had a -8.8% change from baseline. Patients in the placebo group (n=34) had a -0.5% change from baseline.
SURPASS 1 through 5 evaluated the mean change in weight from baseline in adult patients with type 2 diabetes. SURPASS-1 studied Mounjaro monotherapy vs placebo over 40 weeks. The mean baseline weight was 191.8 lb, 190.0 lb, 188.5 lb, and 186.3 lb for Mounjaro 5 mg, Mounjaro 10 mg, Mounjaro 15 mg, and placebo, respectively. Patients taking Mounjaro 5 mg (n=121) had a -14 lb change from baseline. Patients taking Mounjaro 10 mg (n=121) had a -15 lb change from baseline.
Patients taking Mounjaro 15 mg (n=120) had a -17 lb change from baseline. Patients taking placebo (n=113) had a -2 lb change from baseline.
SURPASS-2 studied Mounjaro as an add-on to metformin vs Ozempic 1 mg over 40 weeks. The mean baseline weight was 203.9 lb, 209.0 lb, 206.8 lb, and 206.6 lb for Mounjaro 5 mg, Mounjaro 10 mg, Mounjaro 15 mg, and Ozempic 1 mg, respectively. Patients taking Mounjaro 5 mg (n=470) had a -17 lb change from baseline. Patients taking Mounjaro 10 mg (n=469) had a -21 lb change from baseline. Patients taking Mounjaro 15 mg (n=469) had a -25 lb change from baseline. Patients taking Ozempic 1 mg (n=468) had a -13 lb change from baseline.
SURPASS-3 studied Mounjaro as an add-on to metformin plus or minus a sodium-glucose cotransporter-2 inhibitor vs Tresiba over 52 weeks. The mean baseline weight was 208.1 lb, 206.8 lb, 209.2 lb, and 207.2 lb for Mounjaro 5 mg, Mounjaro 10 mg, Mounjaro 15 mg, and Tresiba, respectively. Patients taking Mounjaro 5 mg (n=358) had a -15 lb change from baseline Patients taking Mounjaro 10 mg (n=360) had a -21 lb change from baseline. Patients taking Mounjaro 15 mg (n=358) had a -25 lb change from baseline. Patients taking Tresiba (n=359) had a +4 lb change from baseline.
SURPASS-4 studied Mounjaro as an add-on to 1-3 oral antihyperglycemic medications (metformin, sulfonylurea, sodium-glucose cotransporter-2 inhibitor) vs insulin glargine over 52 weeks. The mean baseline weight was 199.1 lb, 199.7 lb, 198.4 lb, and 198.9 lb for Mounjaro 5 mg, Mounjaro 10 mg, Mounjaro 15 mg, and insulin glargine, respectively. Patients taking Mounjaro 5 mg (n=328) had a -14 lb change from baseline. Patients taking Mounjaro 10 mg (n=326) had a -20 lb change from baseline. Patients taking Mounjaro 15 mg (n=337) had a -23 lb change from baseline. Patients taking insulin glargine (n=998) had a +4 lb change from baseline.
SURPASS-5 studied Mounjaro as an add-on to basal insulin plus or minus metformin vs placebo over 40 weeks. The mean baseline A1C was 211.2 lb, 208.6 lb, 211.6 lb, and 207.7 lb for Mounjaro 5 mg, Mounjaro 10 mg, Mounjaro 15 mg, and placebo, respectively. Patients taking Mounjaro 5 mg (n=116) had a -12 lb change from baseline. Patients taking Mounjaro 10 mg (n=118) had a -17 lb change from baseline. Patients taking Mounjaro 15 mg (n=118) had a -19 lb change from baseline. Patients taking placebo (n=119) had a +4 lb change from baseline.